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Abstract. Oral mucositis is one of the main complications in
non-surgical cancer treatments. It represents the major dose-
limiting toxicity for some chemotherapeutic agents, for
radiotherapy of the head and neck region and for some radio-
chemotherapy combined treatments. Many reviews and clinical
studies have been published in order to define the best clinical
protocol for prophylaxis or treatment of mucositis, but a
consensus has not yet been obtained. This paper represents an
updated review of prophylaxis and treatment of antineoplastic-
therapy-related mucositis using a MEDLINE search up to May
2006, in which more than 260 clinical studies have been found.
They have been divided according to antineoplastic therapy
(chemotherapy, radiotherapy, chemo-radiotherapy, high-dose
chemotherapy). The prophylactic or therapeutic use of the
analysed agents, the number of enrolled patients and the study
design (randomized or not) were also specified for most studies.
Accurate pre-treatment assessment of oral cavity hygiene,
frequent review of symptoms during treatment, use of traditional
mouthwashes to obtain mechanical cleaning of the oral cavity
and administration of some agents like benzydamine, imidazole
antibiotics, tryazolic antimycotics, povidone iodine, keratinocyte
growth factor and vitamin E seem to reduce the intensity of
mucositis. Physical approaches like cryotherapy, low energy
Helium-Neon laser or the use of modern radiotherapy
techniques with the exclusion of the oral cavity from radiation
fields have been shown to be efficacious in preventing mucositis
onset. Nevertheless a consensus protocol of prophylaxis and
treatment of oral mucositis has not yet been obtained. 
Oral mucositis is one of the main dose-limiting toxicities in
cancer patients. This implies that intensification of non-
surgical cancer therapies is often limited by the presence of
this side-effect. Previously published reviews (1-8) have
pointed out that only a few drugs have been demonstrated to
be effective in preventing or reducing oral mucositis in
patients treated with radio- and/or chemotherapy. Until today
a consensus on the prophylaxis and therapy of anticancer-
therapy-related mucositis has not yet been obtained. In this
review most agents used to prevent or treat oral mucositis
have been examined. The aim of this study was to produce an
updated review of the literature and to summarize the main
studies characteristics in a few tables that could be a rapid
resource for consultation in clinical practice. 
The references for this review were identified by a
comprehensive search of MEDLINE up to May 2006 (with
no language restriction). Papers were selected on the basis
of their relevance to the topic; "mucositis", "chemotherapy"
and "radiotherapy" were the key words used. Preclinical
studies, clinical reviews and consensus meetings were not
included. 
In Table I all the analysed agents are summarized. The
studies are grouped according to treatment modality
(chemotherapy, radiotherapy, radio-chemotherapy, high-dose
chemotherapy), timing of agent administration (prophylaxis
or treatment of mucositis) and study design (phase III
randomized trial or non-phase III randomized trial). Results
are shown in Tables II, III, IV and V. The number of enrolled
patients is also specified for most studies.
In the following sections the classification and the main
mechanisms of action of the analysed agents are briefly
presented. 
Oral Care
Oral cavity hygiene should be considered of great
importance in preventing oral mucositis. Meticulous pre-
treatment assessment with periodontal, dental and
radiographic evaluation and, when necessary, restorative
dental procedures performed at least three weeks before the
beginning of mucosa-toxic therapy, have all been shown to
reduce the incidence and duration of mucositis (9-19).
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The daily review of symptoms combined with a well-
defined strategy for mouth care and analgesic
administration resulted in improved management of
radiation-related mucositis compared with sporadic nursing
intervention and the absence of an analgesic protocol.
Patients with an intensive dental care protocol developed
less painful oral complications compared to the limited
dental care group of patients (107).
In conclusion, most series showed a reduction in the
mucositis incidence and duration when accurate pre-
treatment assessment of oral cavity hygiene was performed
and when a frequent review of symptoms combined with a
well-defined protocol for palliative therapies was given to
all treated patients.
Antiulcer Agents
Sucralfate. Sucralfate is a basic aluminium salt of sucrose
sulfate (sulphated disaccharide) mainly used as a therapeutic
agent in patients with peptic ulcer disease. On ulcerated
mucosa, sucralfate produces a paste-like protective coat,
promotes the local production of prostaglandin E2 (PgE2) and
enhances interleukin 1 and interleukin 2 release from
fibroblasts. It also has a topical anti-inflammatory effect on
oral mucosa. Moreover sucralfate is a well-tolerated agent,
nausea and constipation were reported in only 2% of the
treated patients. Compared with the well established benefit
of sucralfate in pelvic irradiation (127), controversial results
have been obtained in head and neck patients. 
Prostaglandins. Prostaglandins (Pg) are cytoprotective agents
especially for the gastrointestinal tract. Topical application of
Pg has been shown to lead to the healing of chronic leg ulcers.
On the basis of these results, prostaglandins has also been
evaluated in patients with oral mucositis (33, 196-198, 249).
Pentoxifylline. Pentoxifylline is a xanthine derived agent. It
down-regulates the expression of tumor necrosis factor
alpha (TNF-·), which is thought to be correlated with
development of bone marrow transplantation-related
complications. As well as for the treatment of chronic
atrophic leg ulcers, pentoxifylline have also been studied in
oral mucositis (43, 199-204).
Azelastine. Azelastine is a hydrochloride agent with an anti-
inflammatory, antioxidant and antihistaminic action.
Promising results has been obtained in patients with oral
mucositis (250)
Kaolin-pectin. Kaolin is a naturally occurring hydrated
aluminium silicate while pectine is a carbohydrate polymer
consisting primarily of partially methoxylated polygala-
ctouronic acids. Pectin is soluble in water forming a viscous
colloidal solution. Because of these characteristics, Kaolin-
pectin complex is thought to have absorbent and protective
properties, which may be useful in treating oral mucositis.
Physical Therapies
Silver nitrate. Silver nitrate is a caustic agent, which has been
thought to reduce the severity of oral mucositis by
stimulating the regeneration of oral mucosa damaged by
radiation therapy. 
Laser. The application of low-energy Helium-Neon (He-Ne)
laser (so called soft laser) on the oral cavity mucosa which
affects the inflammatory processes is based on a
biochemical effect which increases fibroblast cell division
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Table I. All the analysed agents under review.
Studied agents
Basic oral care
Traditional mouthwashes Saline solution, hydrogen peroxide, 
salt and soda, sterile water, chamomile, 
honey, conventional mouthwashes, 
methylcellulosa, topical fluoride
Benzydamine
Antiulcer agents Sucralfate, prostaglandin, pentoxifylline, 
azelastine, kaolin-pectin
Physical treatments Silver nitrate, low-energy 
Helium-Neon laser, cryotherapy, 
Radiotherapy technique
Growth factors GM-CSF and G-CSF, interleukins,
TGF-‚, KGF, EGF
Infections Antibiotic agents (iseganan, chlorhexidine), 











Miscellaneous group: Coumarin/Troxerutine, proteolytic
enzyme, propantheline, orgotein,
capsaicin, zinc sulfate, oren-Gedoku-to,
syousaikotou, human placental extract,
superoxide dismutase (SOD2), sodium
alginate, prostaglandin inhibitor, uridine,
tetrachlorodacaoxide (TCDO), engineered
biopolimer, bioactive milk factor, aloe,
Formula C, mesalazine, MF5232
(Mucotrol), Flurbiprofen tooth patch
and collagen production as well as a stimulating
mitochondrial cytochrome activities. The molecular effect is
thought to be the neutralisation of the free radicals induced
by chemotherapy and/or radiotherapy with no modification
of oral mucosa vessels perfusion. Soft laser application has
also been demonstrated to produce pain relief by the
modulation of pain perception by modification of nerve
conduction with the release of endorphin and leukephalins. 
Cryotherapy. The topical application of ice chips
(cryotherapy) on the inflamed mucosa is based on the
hypothesis that temporary local vasoconstriction of the oral
mucosa vessels could reduce exposure of the replicating
epithelium cells to peak levels of some cytostatic agents.
Radiotherapy technique. In spite of technical advances,
irradiation of non-target tissue (such as the oral cavity
mucosa) remains unavoidable. The use of different sources
of energy (like heavy particle) or modern three-dimensional
treatment planning (Intensity Modulated Radiation Therapy)
permit to better focus the dose around the target area and
partially protect normal tissue like oral mucosa.
Growth Factors
Granulocyte-monocyte colony stimulating factor (GM-CSF) and
granulocyte colony stimulating factor (G-CSF). Both of these
growth factors have been found to enhance keratinocyte and
fibroblast growth improving the healing of cuts, leg ulcers and
skin grafts. The topical use of both GM-CSF and G-CSF have
also given promising results in the treatment of impaired
wound healing and chronic venous ulcers suggesting that the
mechanism of action of these growth factors could be partially
independent of their systemic action (269-276). 
Interleukin (IL). One of the methods by which GM-CSF may
stimulate cell division in the oral mucosa is by enhancing
interleukin 1 (IL-1) transcription and translation. In animal
studies, IL-1 has been shown to protect normal cells from
radiotherapy- or chemotherapy-related toxicity, while no
protective effect was found on tumour cells (277, 278). Also
interleukin 11 seems to have a range of activities, which
should be potentially relevant to reduce mucositis (169).
Transforming growth factor ‚ (TGF-‚). The mechanism of
action of TGF-‚ is to inhibit cell proliferation by inducing
a reversible arrest of the cell cycle in the G1-phase, a well-
known radioresistant phase. 
Keratinocyte growth factor (KGF). Keratinocyte growth
factor is an epithelial cell-specific growth and differentiation
factor produced by mesenchymal cells. The up-regulation of
KGF after epithelial injury has suggested that it has an
important role in tissue repair. In non-treated animals KGF
has been shown to enhance epithelial thickening, while in
irradiated or chemotherapy-treated mice, it was found to
reduce atrophy, to accelerate regrowth and to decrease
ulcer formation of oral cavity epithelium (279-284).
Epidermal growth factor (EGF). The hypothesis that the
epithelial basal cell rate should be one of the main factors
influencing mucosa sensitivity to cancer therapy-related
toxic effects has been confirmed by a preclinical study (285).
When assessment of changes in salivary EGF in patients
receiving radiation therapy was evaluated, a higher level of
EGF in saliva, prior to and during radiotherapy, was found
to be associated with less severe mucosal damage (286, 287).
Oral Cavity Over-infection
Damage of the oral mucosa during cancer treatments leads
to pathologic colonisation by bacteria, fungi and viruses. In
addition, the reduction of saliva production, which contains
immunoglobulin (IgA) and washes away intraoral debris and
bacteria, may modify the normal bacterial flora lying in the
upper aero-digestive tract. Compared to bacteria and fungi,
viral infection of the oral cavity seems to be a less frequent
clinical complication during radiotherapy or chemotherapy.
Iseganan (a synthetic protegrin with broad-spectrum
microbicidal activity and a lack of systemic absorption) and
clorhexidine (a broad-spectrum antiseptic agent) were
grouped with the antibiotic agents.
Glutamine
Glutamine is a neutral amino acid that acts as a substrate
for nucleotide synthesis in most dividing cells. Animal
studies have suggested that dietary supplementation with
glutamine may protect the gut from both radiotherapy and
chemotherapy side effects (288-289). Glutamine is also used
by cells of the immune system, such as lymphocytes and
macrophages. Incidence of bacteraemia was found to be
lower in patients in which glutamine was used compared
with a control group (290-293).
Anaesthetics
Anaesthetic agents are largely used to reduce mucositis-
related pain. Systemic administration is considered the
standard approach but topical application should have the
potential advantage of local pain control with minimal
systemic side effects and better patient compliance. The main
problem of topical application remains the alteration of taste,
which may exacerbate the hypo-alimentation present during
cancer therapies. For this reason, prophylactic administration
of local anaesthetics should be discouraged. 
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Table II. The studies on chemotherapy-induced mucositis.
Agent Treatment (T) Favourable Not favourable Study design
Prophylaxis (P)
Author No of pts (Bib) Author No of pts (Bib)
Salt and soda T Dodd 23 (20) R
Sterile water P Dodd 222 (21) R
Plant extracts T Matsuoka (22) R
Chamomile PT Mazokipakis 98 (23) NR
P Fidler 164 (24) R
Benzydamine T Sonis (25)
Cheng 34 (26) NR
Sucralfate P Pfeiffer 40 (27) R
PT Allison 40 (28) NR
PT Nottage 81 (29) R
Shenep 48 (30)
T Loprinzi 50 (31) R
Chiara 40 (32)
PgE2 T Porteder 10 (33) NR
Pentoxifylline P Verdi 10 (34) R
He-Ne Laser P Ciais 67 (35) NR
Nes 13 (36)
Wong 15 (37




P Gandara 24 (42) NR
Edelman 46 (43)
Dumontet 22 (44)
Baydar M 40 (45)
Tartarone (46)
GM-CSF T Chi 20 (47) R
Hejna 31 (48)
T Rossi 31 (49) NR
Ibrahim 24 (50)
P Moore 15 (51) NR
PT Mantovani 68 (52) NR
G-CSF PT Katano 14 (53) NR
P Gabrilove 27 (54) NR
P Crawford (55) R
TGF P Wymenga 11 (56) NR
PT Foncuberta 152 (57) NR (m)
KGF P Meropol 18 (58) NR
Iseganan P Giles 323 (59) R
Chlorhexidine T Dodd 23 (60) R
P Cheng 34 (26) Dodd 222 (21) R
Pitten 47 (62)
Wahlin 28 (62)
P Luglie 66 (63) NR
Cheng 42 (64)
Cheng 40 (65)
Nystatin P Barret 66 (33) NR
Amphotericin B T Lefebvre 123 (67) R
Hejna 31 (48)
Miconazole P Brinker 30 (68) R
T Jordan 37 (69) NR
Clotrimazole P Yeo 202 (70) R
T Shechtman 13 (71) R
Table II. continued
Trycyclic Antidepressants
Based on the concept that mucositis-related pain could have
a neuropathic component, some authors have evaluated the
efficacy of tricyclic antidepressants during radiotherapy
and/or chemotherapy.
Amifostine
Amifostine (WR-2721) is a phosphorylated aminothiol
prodrug, which is dephosphorylated by a membrane-bound
alkaline phosphatase to its active metabolite, the free thiol
WR-1065. The mechanism of action of WR-1065 is
scavenging of free radicals created by the action of cytotoxic
therapies on tissue. Compared with tumour tissues, normal
tissue microenvironments generally have higher
concentrations of alkaline phosphatase and are typically less
acid. These characteristics favour selective conversion of
amifostine to its active metabolite in normal tissues.
Amifostine has been demonstrated to have a high level of
uptake in salivary gland tissue, so that its use to diminish the
incidence of xerostomia is appealing. The impact of
amifostine on mucositis is probably due to an indirect effect
related to the enhancement of saliva secretion, which has
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Table II. continued
Agent Treatment (T) Favourable Not favourable Study design
Prophylaxis (P)
Author No of pts (Bib) Author No of pts (Bib)
Fluconazole T Epstein 19 (72) NR
PT Allison 40 (28) NR
T Finlay 73 (73)
Lefebvre 123 (67) R
Antiviral agents T Kubesova 34 (74) NR
Glutamine P Cockerham 21 (75) NR
Skubitz 14 (76)
P Anderson 24 (77) Jebb 28 (79) R
Decker- 24 (78) VanZaanen 20 (80)
Baumann Okuno 134 (81)
Lidocaine T Carnel 18 (82) NR
Turhal 31 (83)
T Dodd 23 (20) R
Benzocaine T LeVeque 28 (84) NR
Redding CR (85)
Dibucaine T Yamamura 23 (86) NR
Doxepin T Epstein 41 (87) NR
Amifostine P DeSouza 29 (88)
Fahlke 27 (89) Stokman 24 (90) NR
Vitamin E T Wadleigh 18 (91) R
Lopez 19 (92)
T Thornley 37 (93) NR
Allopurinol T Clark 6 (94)
Tsavaris 42 (95) Howell 23 (96) NR
T Porta 44 (97) Weiss 52 (98) R
Loprinzi 77 (99)
Pilocarpine P Awidi 32 (100) R
Capsaicin T Berger 11 (101) NR
Oren-gedoku-to P Yuki 40 (102) NR
Syousaikotou P Matsuoka (22) NR
Uridine P Seiter 29 (103) NR
TDCO T Malik (104)
Formula C T Coetxee (105) NR
Bib=bibliografic reference, Author=first author, pts=enrolled patients, R=randomized study, NR=non-randomized study, (m)=multicenter
study, GM-CSF=granulocyte-monocyte colony stimulating factor, G-CSF=granulocyte colony stimulating factor, TGF=transforming growth factor,
KGF=keratinocyte growth factor, TDCO=tetrachlorodacaoxide.
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Table III. The studies on radiotherapy-induced mucositis.
Agent Treatment (T) Favourable Not favourable Study design
Prophylaxis (P)
Author No of pts (Bib) Author No of pts (Bib)
Hydrogen peroxide P Feber 40 (106) R
Saline solution P Feber 40 (106)
R
Salt and soda T Dodd 30 (60) R
Chamomile PT Carl 98 (108) NR
Honey T Biswal 40 (109) R
Conventional 
mouthwashes T Rothwell (110) NR
Benzydamine T Kim Schubert 67 (111) R
Samaranayake (112)
25 (113)
P Epstein 172 (114) R
Sucralfate P Scherlacher 24 (115) Epstein 33 (120) R
Franzen 50 (116) Makkonen 40 (121)
Cengiz 28 (117) Carter 102 (122)
Etiz 44 (118) Lievens 102 (123)
Makkonen 40 (119) Saarilahti 40 (124)
Evensen 60 (125)
PT Allison 40 (28) NR
T Merredith 111 (126) Barker 14 (120) R
Dodd 30 (121)
PgE2 T Porteder 10 (33) NR
Diphenhydramine T Barker 14 (128) R
Misoprostol P Hanson 34 (129) R
Kaolin-Pectin T Barker 14 (128) R
Silver Nitrate P Maciejewski 16 (130) Dorr 13 (131) NR
He-Ne Laser P Bensadoun 30 (132) R
RT tecnique P Perch 125 (133) NR
GM-CSF P Troussard 10 (134) NR
Kannan 10 (135)
P Saarilahti 40 (124) Makkonen 40 (119) R
T Nicolatou 61 (136) NR
Nicolatou 17 (137)
Rovirosa De 20 (138)
La torre (139)
T Masucci 92 (140) R
G-CSF P Mascarin 26 (141) NR
T Wagner 32 (142) NR
P Schneider 14 (143) R
Antibiotic agents P Symonds 275 (144) Stokman 65 (146) R
Okuno 54 (82) Wijers 77 (147)
Matthews 59 (145) El-Sayed 137 (148)
P Spijkervert 15 (149) NR
El-Sayed 17 (150)
Oguchi 52 (151)
Chlorhexidine P Ferretti 30 (152) R
Spijkervet 45 (153) NR
P Spijdervet 30 (154) R
Foote 52 (155)
Samaranayake (133)
Iseganan P Trotti 545 (156) R
Nystatin T Rotwell (110) NR
Amphotericin P Spijkervert 15 (149) NR
Miconazole T Oguchi 25 (151) NR
Clotrimazole P Yeo 202 (70) R
P Matthews 59 (145) NR
Table III. continued
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Table III. continued
Agent Treatment (T) Favourable Not favourable Study design
Prophylaxis (P)
Author No of pts (Bib) Author No of pts (Bib)
T Yap 52 (157) R
Schechtman 13 (71)
Fluconazole P Mucke Belazi 50 (158) NR
39 (159)
T Epstein 19 (72) NR
PT Allison 40 (28) NR
T Lefebvre 123 (67) R
Itraconazole P Belazi 39 (159) NR
Clotrimazole P El-Sayed 137 (150) R
Antiviral 
agents P Bubley 57 (160) R
Glutamine P Huang 17 (161) R
Opioids T Shaiova 14 (162) R
Lidocaine T Carnel 18 (163) NR
Tetracaine T Oguchi Alterio 25 (151)
50 (164) NR
Ketamine T Slatkin (165)
Trycyclic 
antidepressant T Ehrnorooth 43 (166) R
Doxepin T Epstein 41 (87) NR
Amifostine P Antonadou 50 (167) Brizel 315 (169) R
Bourhis 26 (168)




Vitamin E T Ferreira 54 (174) R
Pilocarpine P Valdez Warde 9 (175) Fisher 249 (177) R
130 (176)
Immunoglobulin P Mose 42 (178) NR
Mose 42 (179)
Corticosteroids P Leborgne 66 (180) R
T Rothwell (110) NR
Coumarin/
Troxerutin P Grotz 48 (181) R
Proteolytic 
enzymes P Gujral 100 (182) R
Orgotein T Valencia 41 (183) NR
Capsaicin T Berger 11 (101) NR
Zinc sulfate P Ertekin 30 (184) R
Human 
placental 
extract T Kaushal 120 (185) R
Sodium 
Alginate T Oshitani (39) (186) NR
Pg inhibitors P Pillsbury 19 (187) NR
TCDO T Malik 62 (104) R
P Su 58 (188) NR
Kaolin-Pectin T Barker 14 (127) NR
Formula C T Coetxee 105 NR
Aloe vera P Su 58 (188) R
Flurbiprofen 
tooth patch P Stokman 12 (90) NR
Bib=bibliografic reference, Author=first author, pts=enrolled patients, R=randomized study, NR=non- randomized study, GM-
CSF=granulocyte-monocyte colony stimulating factor, G-CSF=granulocyte colony stimulating factor, TGF=transforming growth factor,
KGF=keratinocyte growth factor, TDCO=tetrachlorodacaoxide.
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Table IV. The studies on high-dose chemotherapy and bone marrow transplant-stem cell transplant- induced mucositis.
Agent Treatment (T) Favourable Not favourable Study design
Prophylaxis (P)
Author No of pts (Bib) Author No of pts (Bib)




mouthwashes T Dazzi 90 (192) R
Methylcellulosa PT Van der Lelie 36 (193) R
Topical fluoride P Papas 95 (194) R(m)
Sucralfate P Castagna 105 (195 R
PgE2 T Pretnar (196) NR
P Labar 60 (197) R
Duenas-G. 15 (198)
Misoprostol P Duenas G. 15 (198) R
Pentoxifylline P Ferra 37 (199) NR
Van der Jagt 49 (200)
Lopez 49 (201)
Stockschlader 92 (202)
Attal Clift 140 (203) R
(204)
He-Ne Laser P Barash 20 (205) R
Cowen 30 (206)
GM-CSF T Gordon Ho 13 (207) NR
Bez 37 (208)
39 (209)
P Cartee 45 (210) Dazzi 90 (211) R
T Nemunaitis 109 (212) Valcarcel 41 (213) R
PT Van der Leile 36 (214) R
G-CSF T Karthaus 8 (215) R
IL11 P Antin 13 (216) R
KGF P Spielberger 212 (217) R
Siddiqui (218)
P Freytes 42 (219) NR
Antibiotic agents P Ferra 37 (199) NR
Chlorhexidine P Mc Gaw 16 (220) Epstein 86 (224) R
Ferretti 51 (221) Weisdorf 100 (225)
Ferretti 40 (222) Raether 47 (226)
Rutkauskas (223)
Nystatine P Epstein 86 (224) R
Fluconazole T Epstein 19 72 NR
P Gava 80 (227) R
Koc 80 (228)
Antiviral agents P Epstein 83 (229) NR
Eisen 60 (230)
Glutamine P Anderson 193 (231) Schloerb 89 (234) R
Aquino 120 (232) Pytlik 40 (235)
Piccirillo 48 (233) Coghlin 58 (236)
Systemic opioids T Coda 119 (237) R
Fentanyl T Denarosi 62 (238) Strupp 74 (239) NR
Pilocarpine P Lockhart 36 (240) R
Vitamin A P Cohen 11 (241) R
Corticosteroid P Ferra 37 (199) NR
Propantheline P Ahmed 20 (242) R
P Oblon 31 (243) NR
Povidone iodine PT Vokurka 132 (191) R
PV701 milk-derived 
GF extract P Prince 98 (244) NR
Mesalazine T Rymes 21 (245) NR
Bib=bibliografic reference, Author=first author, pts=enrolled patients, R=randomized study, NR=non- randomized study, m=multicenter study,
GM-CSF=granulocyte-monocyte colony stimulating factor, G-CSF=granulocyte colony stimulating factor, TGF=transforming growth factor,
KGF=keratinocyte growth factor, TDCO=tetrachlorodacaoxide.
been demonstrated to reduce the intensity of mucositis
(294-296). Topical application of amifostine on oral
mucosae did not seem to provide clinical benefit in patients
treated with epirubicin (297).
Vitamins
Vitamin A. Vitamin A has a significant inhibitory effect on the
inflammation process and epithelial proliferation. A reduction
in vitamin A level was found to be a common condition in
subjects with severe mucositis, and was associated with an
increased risk of Herpes zoster infection (298).
Vitamin E. Vitamin E (·-tocopherol) is an antioxidant agent
which may limit tissue damage from free oxygen radicals
and, thus, may reduce the severity of mucositis during
cancer treatments. 
Allopurinol
The mechanism of action of allopurinol is related to the
inhibition of xanthin oxidase and protease action. For this
reason it has mainly been studied in relation to
chemotherapy-related toxicity.
Povidone Iodine
In in vitro studies, povidone-iodine has been demonstrated
to have good microbicide effect against bacteria, fungi,
protozoa and some viruses but in in vivo trials, only
antibacterial efficacy has been confirmed. In contrast to
other antiseptic agents, povidone-iodine does not lead to
any irritation or damage to the oral mucosa
Pilocarpine
Pilocarpine is thought to reduce mucositis by the
stimulation of saliva production during cancer therapies.
Immunoglobulin
Based on the observation that radiation therapy reduces
salivary and systemic immunoglobulins (Ig) it has been
hypothesised that prophylactic administration of Ig could
reduce oral mucositis.
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Table V. The studies on chemo-radiotherapy- induced mucositis.
Agent Treatment (T) Favourable Not favourable Study design
Prophylaxis (P)
Author No of pts (Bib) Author No of pts (Bib)
Conventional 
mouthwashes T Sprinzl 35 (246) R
Benzydamine T Prada Prada 20 (247) NR
40 (248)
PgE2 T Matejka 15 (249) NR
Azelastine P Osaki 63 (250) NR
GM-CSF P Rosso 29 (251) NR
PT Mantovani 68 (252) NR
PT Sprinzl 35 (253) R
G-CSF P Tejdor 20 (254) Abibitol 70 (255) NR
Nystatin P-T Hasenau (256) NR
Clotrimazole P Yeo 70 (202) R
T Yap 52 (157) R
Shechtman 13 (71)
Fluconazole P Samonis (257) R
Bodey 112 (258)
Opioids T Cerchietti 26 (259) R
Cerchietti 32 (260)
Amifostine P Bruntzel 39 (261) Peters 14 (264) R
Vacha 42 (262) Buentzel 132 (265)
Vacha 53 (263)
P Suntharalingam 19 (266) NR
Povidone iodine P Adamietz 40 (277) R
PT Hasenau (256) NR
MF 5232 (Mucotrol) T Naidu 30 (268) R
Bib=bibliografic reference, Author=first author, pts=enrolled patients, R=randomized study, NR=non-randomized study, GM-CSF=granulocyte-
monocyte colony stimulating factor, G-CSF=granulocyte colony stimulating factor.
Corticosteroids
Corticosteroid agents have an anti-inflammatory action that
could be used in treating oral mucositis.
Miscellaneous Group
All the agents for which only one or two clinical studies
were found in the MEDLINE search and which were not
classified in the previous studied categories have been
included in this group.
Conclusion
The prophylaxis and treatment of oral mucositis during
cancer therapies remains an unsolved problem. Accurate
pre-treatment assessment of oral cavity hygiene, and
mechanical cleaning using traditional mouthwashes seem to
be effective in preventing the onset of oral mucositis. Some
therapeutic agents, such as benzydamine, imidazole
antibiotics, tryazolic antimycotic and povidone iodine, have
shown some clinical evidence of their efficacy in reducing
oral mucositis. Additionaly, some physical therapies, such as
cryotherapy, low energy Helium-Neon laser or exclusion of
the oral cavity from radiation fields have been shown to
reduce oral mucositis. A consensus protocol regarding
prophylaxis and treatment is needed.
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